학술논문
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Document Type
Article
Author
Jørgensen, Kristin K; Olsen, Inge C; Goll, Guro L; Lorentzen, Merete; Bolstad, Nils; Haavardsholm, Espen A; Lundin, Knut E A; Mørk, Cato; Jahnsen, Jørgen; Kvien, Tore K; Berset, Ingrid P; Fevang, Bjørg TS; Florholmen, Jon; Kalstad, Synøve; Mørk, Nils J; Ryggen, Kristin; Tveit, Kåre S; Sæther, Sigrun K; Gulbrandsen, Bjørn; Hagfors, Jon; Waksvik, Kenneth; Warren, David; Henanger, Karoline J.; Asak, Øivind; Baigh, Somyeh; Blomgren, Ingrid M; Bruun, Trude J; Dvergsnes, Katrine; Frigstad, Svein O; Gjesdal, Clara G; Grandaunet, Berit H J; Hansen, Inger M; Hatten, Ingvild S H; Huppertz-Hauss, Gert; Henriksen, Magne; Hoie, Sunniva S; Krogh, Jan; Kruse, Julia R; Ljoså, Maud-Kristine A; Midtgard, Irina P; Mielnik, Pawel; Moum, Bjørn; Noraberg, Geir; Poyan, Armin; Prestegård, Ulf; Rashid, Haroon U; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine A; Skjetne, Kristine; Strand, Eldri K; Stray, Hilde; Stray, Njaal; Torp, Roald; Vold, Cecilia; Ystrøm, Carl M; Zettel, Camilla C
Source
The Lancet; June 2017, Vol. 389 Issue: 10086 p2304-2316, 13p
Subject
Language
ISSN
01406736; 1474547X
Abstract
TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity.